Comparison of the Working Formulation of non-Hodgkin’s lymphoma with the Rappaport, the Kiel, and the Lukes-Collins Classifications. Correlations and prognostic value

  • J. Ersbøll
  • H. B. Schultz
  • N. I. Nissen
  • P. Hougaard
  • K. Hou-Jensen
Part of the Developments in Oncology book series (DION, volume 32)


The Rappaport classification of non-Hodgkin’s lymphoma [1] gained universal acceptance as a valuable basic diagnostic language for communication of therapeutic results among medical centers in the period 1968–75. Recognition that non-Hodgkin’s lymphomas represent neoplasms of the lymphocytic immune system has resulted in new classifications based upon modern concepts of the T- and B-lymphocyte systems [2, 3]. Other newer classification schemes have challenged the terminology used by Rappaport [4–6], and the Rappaport system itself has been modified several times [7–9]. The existence and the use of many histologic classifications for the non-Hodgkin’s lymphomas prompted the United States National Cancer Institute to sponsor a large international multi-institutional clinicopathologic study comparing six classifications. The results were published in 1982, and two important conclusions were reached [10]: ‘First, each system is successful in separating a large group of patients into subgroups with a spectrum of prognoses varying from good to poor survival. Second, no system appears superior to any other in this respect’. Based on this study, the investigators reached consensus on a ‘Working Formulation of non-Hodgkin’s Lymphoma for Clinical Usage’.


Malignant Lymphoma Working Formulation Lymphoma Entity Kiel Classification United States National Cancer Institute 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rappaport H (1966). Tumors of the hemopoietic system. In: Atlas of Tumor Pathology, Section 3, Fascicle 8. Washington DC: US Armed forces Institute of Pathology.Google Scholar
  2. 2.
    Lennert K, Mohri N, Stein H and Kaiserling E (1975). The histopathology of malignant lymphoma. Br J Haematol (suppl) 31: 193–203.CrossRefGoogle Scholar
  3. 3.
    Lukes RJ and Collins RD (1974). Immunologic characterization of human malignant lymphomas. Cancer 34: 1488–1503.PubMedCrossRefGoogle Scholar
  4. 4.
    Dorfman RF (1974). Classification of non-Hodgkin’s lymphoma. Lancet 1: 1295.PubMedCrossRefGoogle Scholar
  5. 5.
    Bennett MH, Farrer-Brown G, Henry K and Jelliffe AM (1974). Classification of non-Hodgkin’s lymphomas. Lancet 2: 405–406.CrossRefGoogle Scholar
  6. 6.
    Mathe G, Rappaport H, O’Conor GT and Torlani H (1976). Histological and cytological typing of neoplastic diseases of hemopoietic and lymphoid tissues. In: WHO International Histological Classification of Tumours, no 14. Geneva: World Health Organization.Google Scholar
  7. 7.
    Nathwani BN, Kim H and Rappaport H (1976). Malignant lymphoma lymphoblastic. Cancer 38: 964–983.PubMedCrossRefGoogle Scholar
  8. 8.
    Rappaport H 1977 ). Non-Hodgkin’s lymphomas: Roundtable discussion of histopathologic classifications. Cancer Treat Rep 61: 1037–1042.Google Scholar
  9. 9.
    Nathwani BN (1979). A critical analysis of the classifications of non-Hodgkin’s lymphomas. Cancer 44: 347–384.PubMedCrossRefGoogle Scholar
  10. 10.
    The Non-Hodgkin’s Lymphoma Pathologic Classification Project (1982). National Cancer Institute sponsored study of classification of non-Hodgkin’s lymphomas: Summary and description of a working formulation for clinical usage. Cancer 49: 2112–2135.CrossRefGoogle Scholar
  11. 11.
    Lennert K and Mohri N (1978). Histopathology and diagnosis of non-Hodgkin’s lymphomas. In: Malignant Lymphomas Other Than Hodgkin’s Disease, pp. 111–469. New York: Springer Verlag.Google Scholar
  12. 12.
    Carbone PP, Kaplan HS, Musshoff K et al. (1971). Report on the Committee on Hodgkin’s Disease Staging Classification. Cancer Res 31: 1860–1861.PubMedGoogle Scholar
  13. 13.
    Nissen NI, Ersboll J, Hansen HS et al. (1983). Randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin’s lymphomas. Cancer 52: 1–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Kaplan EL and Meier P (1958). Nonparametric estimation from incomplete observations. Amer J Stat Assoc J 53: 457–481.CrossRefGoogle Scholar
  15. 15.
    Peto R, Pike MC, Armitage P et al. (1977). Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35: 1–39.PubMedCrossRefGoogle Scholar
  16. 16.
    Cox DR (1972). Regression models and life tables (with discussion). J Roy Statist Soc B 34: 187–220.Google Scholar
  17. 17.
    Krüger G, Grisar T, Lennert K et al. (1981). Histopathological correlation of the Kiel with original Rappaport classification of malignant non-Hodgkin’s lymphomas. Blut 43: 167–181.PubMedCrossRefGoogle Scholar
  18. 18.
    Hoppe RT (1982). A Working Formulation of Non-Hodgkin’s Lymphomas for Clinical Usage: Clinicopathological and prognostic correlations. In: Rosenberg SA and Kaplan HS (Eds.). Malignant Lymphomas. Etiology, Immunology, Pathology, Treatment, pp. 469–483. New York: Academic Press.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1985

Authors and Affiliations

  • J. Ersbøll
    • 1
  • H. B. Schultz
    • 1
  • N. I. Nissen
    • 1
  • P. Hougaard
    • 1
  • K. Hou-Jensen
    • 1
  1. 1.The Finsen Institute, and Statistical Research UnitUniversity of CopenhagenDenmark

Personalised recommendations